Between‐Batch Pharmacokinetic Variability Inflates Type I Error Rate in Conventional Bioequivalence Trials: A Randomized Advair Diskus Clinical Trial

We previously demonstrated pharmacokinetic differences among manufacturing batches of a US Food and Drug Administration (FDA)‐approved dry powder inhalation product (Advair Diskus 100/50) large enough to establish between‐batch bio‐inequivalence. Here, we provide independent confirmation of pharmaco...

Descripción completa

Detalles Bibliográficos
Autores principales: Burmeister Getz, E, Carroll, KJ, Mielke, J, Benet, LZ, Jones, B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5324827/
https://www.ncbi.nlm.nih.gov/pubmed/27727445
http://dx.doi.org/10.1002/cpt.535

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5324827/
https://www.ncbi.nlm.nih.gov/pubmed/27727445
http://dx.doi.org/10.1002/cpt.535

Ejemplares similares